CN211382843U - Intestinal canal transmission developing capsule - Google Patents
Intestinal canal transmission developing capsule Download PDFInfo
- Publication number
- CN211382843U CN211382843U CN201921900415.9U CN201921900415U CN211382843U CN 211382843 U CN211382843 U CN 211382843U CN 201921900415 U CN201921900415 U CN 201921900415U CN 211382843 U CN211382843 U CN 211382843U
- Authority
- CN
- China
- Prior art keywords
- barium
- capsule
- bead
- intestinal
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The utility model provides an intestinal transmission developing capsule, the utility model discloses through establishing barium pearl and barium powder in the capsule shell, after the patient swallows the barium agent capsule, the capsule first selects to pass through the oral cavity, then reaches the small intestine along the alimentary canal, and the capsule shell is cracked completely at this moment and is absorbed, releases barium pearl and barium powder, and barium pearl and barium powder can simulate the transmission orbit of food; a doctor shoots an abdominal X-ray plain film for a patient at different time intervals, knows the quadrant where the barium bead is located by observing the position of the barium bead, and determines the intestinal canal where the barium bead is located through the transmission track left in the intestinal tract by the barium powder; the number of barium beads in different intestinal canals at different time periods can be used for accurately judging which intestinal canals have the slow transmission phenomenon; the developing capsule can be used for accurately judging the intestinal canal with the slow transmission phenomenon and improving the diagnosis efficiency. The utility model discloses simple structure is novel, is convenient for produce manufacturing, low cost uses simple and easy, is worth clinical popularization.
Description
Technical Field
The utility model relates to a medical developer technical field, concretely relates to intestinal transmission development capsule.
Background
In the clinical diagnosis of chronic constipation, colon transmission tests are usually required for slow transit constipation, and common visualization products are opaque metal pellets, barium rings or barium bars. Because the developing product is opaque, after the developing product enters the intestinal tract, the developing product can be observed after X-ray development, the number of the opaque pellets in different quadrants is calculated, the percentage of the pellets in the possible intestinal tract is estimated, and whether the colon slow transmission phenomenon exists in the possible intestinal tract or not is presumed. However, the position of the intestinal canal can be changed due to the lengthy intestinal canal, so that the positioning difficulty is very easy to cause and the misdiagnosis is caused; in addition, the judgment of the intestinal canal is not accurate only through the quadrant where the small ball is located.
As the doctor takes the developing product by mixing the barium agent and the porridge and swallows the developing product at the same time, the quadrant where the developing product is located is judged through the developing product, and the section of the intestinal canal where the developing product is specifically located is judged through the track of the food paste containing the barium agent. The patient needs to take the developing product and the barium meal at the same time, and the barium meal is easy to enter the appendix and is difficult to be discharged; and the small dose of barium has a disadvantage that after entering the colon, the barium is easy to absorb water by the colon, so that the barium can not be attached to the colon wall and can not move, and at the moment, the problem of intestinal canal transmission or barium adherence cannot be judged, and improvement is needed.
SUMMERY OF THE UTILITY MODEL
The utility model aims at providing an intestinal transmission development capsule aims at optimizing the structure of the supplementary medicament of current intestinal development.
In order to achieve the above purpose, the utility model discloses a following technical scheme realizes:
an enteric transmission developing capsule comprises round bead barium beads and a capsule shell; the barium beads are of a solid bead structure; a plurality of holes are uniformly distributed on the surface of the barium bead; barium powder is filled in the holes; the capsule shell is tightly wrapped outside the barium beads, so that the barium powder in the holes is blocked.
Optionally, the capsule shell is a spherical shell-like structure and is matched to the barium bead size.
Optionally, the capsule shell is a dissolvable hollow shell-like structure.
Optionally, the barium beads are bead-like structures with a diameter of 5 mm.
Optionally, the barium powder is an aggregate of discrete barium-containing particles having a particle size of less than 10 mesh.
Compared with the prior art, the beneficial effects of the utility model are that:
1. the utility model discloses a patient swallows a plurality of development capsules after, the capsule is first-selected through the oral cavity, then reachs the small intestine along the alimentary canal, and the capsule shell schizolysis is absorbed completely this moment, releases barium pearl and barium powder, and the transmission orbit of barium pearl and barium powder simulative food, shoots the belly X line plain film for the patient through the doctor at different periods, and the doctor of being convenient for observes the diagnosis.
Of course, it is not necessary for any particular product to achieve all of the above-described advantages at the same time.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
Fig. 1 is a schematic structural view of a developing capsule according to an embodiment of the present invention;
FIG. 2 is a schematic structural diagram of a barium bead-coated capsule shell according to another embodiment of the present invention;
FIG. 3 is a schematic diagram of a barium bead structure according to another embodiment of the present invention;
FIG. 4 is a schematic view of a developing capsule according to another embodiment of the present invention;
the reference numbers in the figures illustrate:
1. barium beads; 2. a capsule shell; 3. barium powder; 4. developing the filaments; 5. and (4) holes.
Detailed Description
To make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the embodiments of the present invention are combined to clearly and completely describe the technical solution in the embodiments of the present invention, and obviously, the described embodiments are some embodiments of the present invention, not all embodiments. Based on the embodiments in the present invention, all other embodiments obtained by a person skilled in the art without creative efforts belong to the protection scope of the present invention.
The present invention will be further explained with reference to the accompanying drawings 1 to 3:
referring to fig. 1, in one embodiment, an enteric transmission developing capsule comprises barium beads 1, a capsule shell 2 and barium powder 3; the barium beads 1 and the barium powder 3 are arranged in the capsule shell 2.
The capsule shell 2 is a soluble hollow shell-like structure.
A plurality of barium beads 1 and barium powder 3 are mixed and arranged in the capsule shell 2; preferably, 15 barium beads with the diameter of 5mm and barium powder are mixed in the capsule shell; and the barium powder 3 is an aggregate of discrete barium-containing particles having a particle size of less than 250 microns.
The utility model discloses a many portions barium pearl 1 and barium powder 3 mix in capsule shell 2, after the patient swallows the barium agent capsule, the capsule is first selected through the oral cavity, then reachs the small intestine along the alimentary canal, and capsule shell 2 schizolysis is absorbed completely this moment, releases barium pearl 1 and barium powder 3, and the transmission orbit of barium pearl 1 and barium powder 3 simulative food. The doctor shoots the abdomen X line plain film for the patient at different periods, because barium 1 pearl density is higher, the accessible is observed 1 position of barium and is known its place quadrant, and the transmission orbit that rethread barium powder 3 left can confirm the intestines tube that barium 1 pearl is located, the doctor's of being convenient for observation diagnosis. According to the number of the barium beads 1 in different intestinal canals at different time periods, which intestinal canals have the slow transmission phenomenon can be accurately judged, and the effective diagnosis of doctors is greatly improved.
The barium beads 1 are of a spherical block structure, and are easy to roll through the spherical structure. The barium beads 1 are compacted solid bead-shaped structures formed by pressing barium sulfate powder and excipients.
With reference to fig. 2 and fig. 3, in another embodiment, different from the above embodiment, a plurality of holes 5 are uniformly distributed on the surface of the barium bead 1, barium powder 3 is filled in the holes 5, and the capsule shell 2 is tightly wrapped outside the holes 5 of the barium bead 1, so as to realize the plugging of the barium powder 3.
The capsule shell 2 is of a spherical shell-shaped structure and is matched with the barium bead 1 in size.
A plurality of holes 5 for accommodating barium powder 3 are uniformly distributed on the periphery of the barium bead 1.
The barium beads 1 are in a bead-shaped structure with the diameter of 5-10 mm.
Preferably, the barium bead 1 is prepared by taking 40% of modified barium sulfate and 60% of medical polyethylene, uniformly stirring and mixing at a high speed, then extruding and granulating by a double-screw extruder, and performing injection molding on granules by an injection molding machine.
In the embodiment, the capsule shells 2 are used for sealing the holes 5 on the barium beads 1, so that after a patient swallows a proper amount of barium bead capsules (about 20 barium bead capsules), the capsule shells 2 on the surfaces of the barium beads 1 are completely cracked and absorbed in the small intestine, and the barium beads 1 can release the barium powder 3 in the holes 5 in the transmission process, so that the transmission track of food can be simulated. The doctor shoots the abdominal X-ray plain film for the patient at different periods, knows the quadrant in which the barium bead is located by observing the position of the barium bead 1, and then can determine the intestinal canal in which the barium bead 1 is located through the transmission track left by the barium powder 3. According to the number of the barium beads 1 in different intestinal canals in different time periods, which intestinal canals have the slow transmission phenomenon can be accurately judged.
It should be noted that the trend of the intestinal tract of the patient is displayed by observing the distribution form of a large amount of barium powder in the intestinal tract and the advancing condition of the barium powder along with the contents, the anatomical structure of the intestinal tract of the patient can be observed in an auxiliary manner, the intestinal segment where the marker is located can be accurately judged, the number of the markers in each quadrant can be further determined, and the accuracy of data statistics of the markers can be improved.
In another embodiment, different from the previous embodiment, with reference to fig. 4, there is provided a barium bar, capsule shell 2 and developer filament 4; the barium strip and the developing filament 4 are uniformly mixed within the capsule shell 2.
The developing filaments 4 may be classified into three types: the first type is barium wadding, i.e. cotton dipped with barium sulfate powder; the second type is developable polymer filament (nondegradable), which is formed by mixing barium sulfate and nondegradable polymer materials (PP, PE, silicone rubber); the third type is developable polymer filament (degradable) formed by mixing barium sulfate and degradable polymer material (polylactic acid and copolymer thereof).
Wherein the barium strips and the barium wadding 4 are mixed inside the capsule shell 2. After the barium capsule is swallowed by a patient, the barium capsule firstly passes through the oral cavity and then reaches the small intestine along the digestive tract, the capsule shell 2 is completely cracked and absorbed at the moment, the barium bar 1 and the developing silk-shaped object 4 are released, and the barium bar and the developing silk-shaped object 4 can simulate the transmission track of food. The doctor is higher for the patient shoots the belly X line plain film at different periods, by barium strip density, and is bulky, and it is obvious to develop, and its place quadrant is known to its position of accessible observation, and the rethread develops "water shadow appearance" transmission orbit that silk 4 left, and the intestines tube moves towards more clear, is convenient for confirm the intestines tube at barium strip place. According to the number of the barium bars in different intestinal canals in different time periods, which intestinal canals have the slow transmission phenomenon can be accurately judged.
Preferably, the barium bar is prepared by taking a proper amount of barium sulfate powder, PLGA, PEG4000 and essence, premixing the barium sulfate powder, the PLGA, the PEG4000 and the essence according to a certain proportion, pressing the mixture into a strip-shaped structure by a special die on a self-made medicine pressing machine, and demolding.
For example, 30g of barium sulfate powder, 65g of PLGA (7525) (intrinsic viscosity about 20ml/g), 14g of PEG4000 and 1.5g of essence are uniformly mixed, weighed, filled, pressed under pressure, kept in pressure and taken out of a mould to obtain about 200 barium bars on a special medicine pressing machine, and the finished product is obtained after packaging.
When the utility model is used by the structure in the above embodiment, the patient swallows the marker capsule (gastric soluble), enters the alimentary canal through the oral cavity, and releases barium-containing particles and barium powder after the capsule shell is cracked; the abdomen X-ray plain film is shot for a patient by a doctor at different time intervals, and the time of developing substances passing through the stomach and small intestine of the patient is observed to assist in judging the power condition of the stomach and small intestine; after a patient swallows the marker capsule (enteric coated capsule), the capsule passes through the oral cavity and reaches the small intestine along the digestive tract, and barium-containing particles and barium powder are released, the texture of the capsule is similar to that of intestinal contents, and the propelling process of the contents in the intestine can be simulated to the maximum extent; observing the motion condition of the marker by observing the abdominal X-ray plain film shot by the doctor for the patient at different time intervals so as to diagnose the colorectal dynamic condition of the patient; the invention has simple and novel structure, convenient production and manufacture and low cost, can accurately judge the intestinal canal with slow transmission phenomenon by using the developer, judges the constipation of a patient according to the discharge rate of the marker within a certain time, greatly improves the diagnosis efficiency and is worthy of clinical popularization.
It should be noted that the detailed description of the present invention is well known in the art, and the detailed connection method can be widely used in daily life without creative efforts by those skilled in the art, and will not be described in detail herein.
In the description of the present invention, it is to be understood that the terms "center", "longitudinal", "lateral", "length", "width", "thickness", "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", "clockwise", "counterclockwise", "axial", "radial", "circumferential", and the like, indicate the orientation or positional relationship indicated based on the drawings, and are only for convenience of description and simplicity of description, and do not indicate or imply that the device or element referred to must have a particular orientation, be constructed and operated in a particular orientation, and therefore, should not be construed as limiting the present invention.
Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one such feature. In the description of the present invention, "a plurality" means at least two, e.g., two, three, etc., unless specifically limited otherwise.
In the present invention, unless otherwise expressly stated or limited, the terms "mounted," "connected," and "fixed" are to be construed broadly and may, for example, be fixedly connected, detachably connected, or integrally formed; can be mechanically or electrically connected; they may be directly connected or indirectly connected through intervening media, or they may be connected internally or in any other suitable relationship, unless expressly stated otherwise. The specific meaning of the above terms in the present invention can be understood according to specific situations by those skilled in the art.
In the present application, unless expressly stated or limited otherwise, the first feature may be directly on or directly under the second feature or indirectly via intermediate members. Also, a first feature "on," "over," and "above" a second feature may be directly or diagonally above the second feature, or may simply indicate that the first feature is at a higher level than the second feature. A first feature being "under," "below," and "beneath" a second feature may be directly under or obliquely under the first feature, or may simply mean that the first feature is at a lesser elevation than the second feature.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art without departing from the scope of the present invention.
Claims (4)
1. An intestinal tract transmission developing capsule is characterized in that: comprises a bead-shaped barium bead (1) and a capsule shell (2); the barium beads (1) are of a solid bead structure; a plurality of holes (5) are uniformly distributed on the surface of the barium bead (1); the holes (5) are filled with barium powder (3); the capsule shell (2) is tightly wrapped outside the barium bead (1), so that the barium powder (3) in the hole (5) is blocked.
2. The enteric delivery developing capsule of claim 1, wherein: the capsule shell (2) is of a spherical shell structure and is matched with the barium bead (1) in size.
3. The enteric delivery developing capsule of claim 1, wherein: the capsule shell (2) is a soluble hollow shell-like structure.
4. The enteric delivery developing capsule of claim 1, wherein: the barium beads (1) are in a bead-shaped structure with the diameter of 5 mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201921900415.9U CN211382843U (en) | 2019-11-06 | 2019-11-06 | Intestinal canal transmission developing capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201921900415.9U CN211382843U (en) | 2019-11-06 | 2019-11-06 | Intestinal canal transmission developing capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN211382843U true CN211382843U (en) | 2020-09-01 |
Family
ID=72221562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201921900415.9U Active CN211382843U (en) | 2019-11-06 | 2019-11-06 | Intestinal canal transmission developing capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN211382843U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110639028A (en) * | 2019-11-06 | 2020-01-03 | 姜从桥 | Intestinal tract developer and preparation method thereof |
-
2019
- 2019-11-06 CN CN201921900415.9U patent/CN211382843U/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110639028A (en) * | 2019-11-06 | 2020-01-03 | 姜从桥 | Intestinal tract developer and preparation method thereof |
| CN110639028B (en) * | 2019-11-06 | 2022-07-15 | 姜从桥 | Intestinal tract developer and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goyanes et al. | PET/CT imaging of 3D printed devices in the gastrointestinal tract of rodents | |
| US11622940B2 (en) | Solid forms and methods of preparing the same | |
| Zheng et al. | Melt extrusion deposition (MED™) 3D printing technology–A paradigm shift in design and development of modified release drug products | |
| CN101773674B (en) | Gastrointestinal motivity marker capsule | |
| JP7394775B2 (en) | gastric stay electronics | |
| CN211382843U (en) | Intestinal canal transmission developing capsule | |
| TW201240679A (en) | Pharmaceutical formulations | |
| HU215971B (en) | Process for producing orally administered suspended pharmaceutical composition | |
| CN102091335A (en) | Gastrointestinal transit disorder diagnosis composition and use thereof | |
| CN108601724A (en) | gastric retention device | |
| CN111249257A (en) | 3D printing drug sustained-release capsule and preparation method and application thereof | |
| Prajapati et al. | Development of modified release gliclazide biological macromolecules using natural biodegradable polymers | |
| CN108348472A (en) | The tablet containing high dose mesalazine of optimization | |
| CN104352441A (en) | DMF (dimethyl fumarate) enteric-coated micropellet and preparation method thereof | |
| CN109589491B (en) | Automatic drug delivery device | |
| CN110639028B (en) | Intestinal tract developer and preparation method thereof | |
| CN209770914U (en) | Marker for gastrointestinal motility examination | |
| CN107308127A (en) | C14H10Cl2NNaO2 multi-unit sustained-release pellet tablet | |
| CN1814306A (en) | Digestive tract evacuation-detecting slow-release tablet and its preparing process | |
| CN103919716B (en) | A kind of segmented intestine targeted type pH sensitive aquagels and its preparation method and application | |
| CN210228874U (en) | Automatic medicine feeder | |
| Fatema et al. | Gastroretentive drug delivery system: an overview | |
| CN100354007C (en) | Skeleton tablet core for digestive tract evacuation-detecting slow-release tablet and its preparing process | |
| CA3130184A1 (en) | Capsule shell comprising a core-shell polymer and a cellulose | |
| Mali et al. | A review on gastro retentive floating drug delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |